Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Francesco SchettiniEva BlondeauxChiara MolinelliRaphaëlle BasHee Jeong KimAntonio di MeglioRinat Bernstein MolhoSabine C LinnKatarzyna PogodaEstela CarrascoKevin PunieElisa AgostinettoNerea Lopetegui LiaKelly-Anne PhillipsAngela TossChristine Rousset-JablonskiMarion AcheritogarayAlberta FerrariShani Paluch-ShimonRobert FruscioWanda CuiStephanie M WongClaudio VernieriMaria Vittoria DieciAlexios MatikasMariya RozenblitCynthia Villarreal GarzaDe Marchis LauraFabio PuglisiLeonor Vasconcelos de MatosMonica MariñoLuis TeixeiraRossella GraffeoAlessia RognoneAlessandra ChircoNicoleta AntoneYara G AbdouMaximilian MarholdIvana Božović-SpasojevićCortes Salgado AlfonsoLuca CarmiscianoMarco BruzzoneCurigliano GiuseppeAleix PratMatteo LambertiniPublished in: Cancer (2024)
In young patients with HER2-negative BC and germline BRCA1/2 PVs, HER2-low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal-like disease. HER2-low status was associated with a modestly improved prognosis.